Clinical Trial Update: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the safety, pharmacokinetics, and efficacy of KRN23 in pediatric Chinese patients with X-linked hypophosphatemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: X-linked Hypophosphatemia (XLH) | Phase 4 | Status: COMPLETED